NCT04951635 - A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

July 15, 2024

Study Completion Date

January 15, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Almonertinib

"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."

DRUG

Placebo Almonertinib

"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital, Ji'nan